Vaishali Pharma's Q1 FY 2026-27 Quarterly Results

Result Summary

• Vaishali Pharma Ltd reported a 16.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 4.6%.
• Its expenses for the quarter were down by 22.3% QoQ and 4.8% YoY.
• The net profit increased 307.9% QoQ and increased 21.1% YoY.
• The earnings per share (EPS) of Vaishali Pharma Ltd stood at 0.12 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Vaishali Pharma Ltd is a company operating within the pharmaceutical industry. It primarily focuses on the development, manufacture, and sale of pharmaceutical products and related services. These may include a wide range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and healthcare solutions. As of the data available up to October 2023, no specific recent major developments are outlined for Vaishali Pharma Ltd. However, the company continues to participate actively in the pharmaceutical market, focusing on delivering quality healthcare products and expanding its market presence.

Revenue

In the first quarter of FY27, Vaishali Pharma Ltd reported a total income of ₹23.47 crores. This represents a decrease of 16.7% from the previous quarter (Q4FY26), where the total income was ₹28.19 crores. Comparing year-over-year, the total income shows a decline of 4.6% from ₹24.59 crores in Q1FY26. These changes indicate fluctuations in revenue generation over the quarters and year, reflecting dynamic market conditions or operational adjustments within the company.

Profitability

During Q1FY27, Vaishali Pharma Ltd achieved a profit before tax of ₹1.73 crores, which is a significant increase from ₹0.18 crores in Q4FY26, marking a quarter-over-quarter growth of 861.1%. Year-over-year, the profit before tax remained relatively stable, with a slight decrease of 0.6% from ₹1.74 crores in Q1FY26. The tax expense for Q1FY27 was ₹0.24 crores, contrasting with a tax credit of ₹-0.09 crores in the prior quarter, reflecting a substantial shift. The profit after tax rose to ₹1.55 crores, exhibiting a 307.9% increase from the previous quarter and a 21.1% rise compared to the same quarter in the prior year. Earnings per share for this quarter stood at ₹0.12, up from ₹0.03 in Q4FY26.

Operating Metrics

Total expenses for Vaishali Pharma Ltd in Q1FY27 amounted to ₹21.75 crores, which is a reduction of 22.3% from the previous quarter's expenses of ₹28.01 crores. Year-over-year, expenses decreased by 4.8% from ₹22.85 crores in Q1FY26. This reflects the company's ability to manage its costs effectively despite variations in total income. The relationship between total income and expenses indicates a focus on optimizing operational efficiency. The data provided does not include information to calculate additional financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, limiting further analysis in this area.